CLINICAL TRIALS PROFILE FOR COPAXONE
✉ Email this page to a colleague
All Clinical Trials for Copaxone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00039988 ↗ | Treatment of Multiple Sclerosis With Copaxone and Albuterol | Completed | Autoimmunity Centers of Excellence | N/A | 2001-11-01 | The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse. |
| NCT00039988 ↗ | Treatment of Multiple Sclerosis With Copaxone and Albuterol | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 2001-11-01 | The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse. |
| NCT00078338 ↗ | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis | Completed | Pfizer | Phase 4 | 2004-02-16 | The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis. |
| NCT00078338 ↗ | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis | Completed | EMD Serono | Phase 4 | 2004-02-16 | The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Copaxone
Condition Name
Clinical Trial Locations for Copaxone
Trials by Country
Clinical Trial Progress for Copaxone
Clinical Trial Phase
Clinical Trial Sponsors for Copaxone
Sponsor Name
